A detailed history of Qube Research & Technologies LTD transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 215,690 shares of ATNM stock, worth $306,279. This represents 0.0% of its overall portfolio holdings.

Number of Shares
215,690
Holding current value
$306,279
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.72 - $8.0 $370,986 - $1.73 Million
215,690 New
215,690 $405,000
Q1 2024

May 14, 2024

BUY
$5.0 - $9.2 $15,965 - $29,375
3,193 New
3,193 $25,000
Q1 2023

May 15, 2023

BUY
$8.51 - $14.26 $305,228 - $511,463
35,867 Added 159.61%
58,339 $551,000
Q4 2022

Feb 14, 2023

SELL
$7.05 - $14.41 $4,815 - $9,842
-683 Reduced 2.95%
22,472 $239,000
Q3 2022

Nov 14, 2022

BUY
$4.81 - $8.48 $19,807 - $34,920
4,118 Added 21.63%
23,155 $171,000
Q2 2022

Aug 15, 2022

BUY
$4.71 - $7.11 $89,664 - $135,353
19,037 New
19,037 $92,000

Others Institutions Holding ATNM

About Actinium Pharmaceuticals, Inc.


  • Ticker ATNM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,184,700
  • Market Cap $35.8M
  • Description
  • Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...
More about ATNM
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.